SCISYS has reported a strong H1 with professional fees jumping 24%. However, this was off a weak H117 and some business was brought forward from H2. Consequently, we are forecasting a more balanced H1/H2 in FY18. We have increased our FY18 revenues by £3.0m to reflect this balancing, but we have maintained our profit forecasts. All divisions posted record revenues, the order book remains robust at close to £100m and net debt continues to decline. Management’s goal of £60m in revenues and double-digit margins within the next few years looks increasingly conservative and we believe the stock is solid on c 14.6x our FY19e EPS.
Written by
SCISYS |
Strong H1 but more balanced year is expected |
Interim results |
Software & comp services |
20 September 2018 |
Share price performance
Business description
Next events
Analysts
SCISYS is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||
SCISYS has reported a strong H1 with professional fees jumping 24%. However, this was off a weak H117 and some business was brought forward from H2. Consequently, we are forecasting a more balanced H1/H2 in FY18. We have increased our FY18 revenues by £3.0m to reflect this balancing, but we have maintained our profit forecasts. All divisions posted record revenues, the order book remains robust at close to £100m and net debt continues to decline. Management’s goal of £60m in revenues and double-digit margins within the next few years looks increasingly conservative and we believe the stock is solid on c 14.6x our FY19e EPS.
Year |
Revenue |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/16 |
45.7 |
3.0 |
9.2 |
1.96 |
20.2 |
1.1 |
12/17 |
57.2 |
3.8 |
10.0 |
2.16 |
18.5 |
1.2 |
12/18e |
56.0 |
4.4 |
12.0 |
2.38 |
15.4 |
1.3 |
12/19e |
60.1 |
5.0 |
12.7 |
2.62 |
14.6 |
1.4 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. IFRS 15 is applied from 1 January 2018.
H1 results: Professional fees jump 24% to £27.6m
Group revenue rose by 13% to £28.7m, while adjusted operating profit more than doubled to £2.5m. The Enterprise Solutions & Defence and Space divisions reported strong contribution growth whereas M&B and Annova recorded declines despite record sales. M&B and Annova are being integrated into a single business unit. The interim dividend has been increased by 10% to 0.65p.
New £2m contract win with Transport for London
Earlier this week SCISYS announced it has won a £2m contract to provide software design, development and support services to Transport for London (TfL) for its timetabling and scheduling as part of its Future Bus Systems programme.
Brexit redomicile decision to be made by end 2018
The company says it still does not expect any adverse operational consequences as a result of Brexit. However, it is obliged to protect its positions on Galileo and EGNOS if Brexit proceeds without specific amendments. We anticipate a decision to redomicile the group is likely to be made next month.
Forecasts: Moving up revenues, earnings maintained
We have increased our revenue forecasts by £3.0m in FY18 to £56.0m and by £3.1m in FY19 to £60.1m. We have conservatively maintained our profits forecasts and continue to forecast end FY18 net debt of £3.0m.
Valuation: Profits maintained for now
The stock trades on c 15.4x our earnings in FY18e, falling to c 14.6x in FY19e. Alternatively, the stock trades on c 0.95x our FY19e sales and c 8.5x EBITDA, which we believe is attractive if SCISYS can maintain the momentum. Our DCF model, which is based on our forecasts and organic CAGR of 3.5% over 10 years, a weighted average cost of capital of 10% and an 11.0% long-term margin target, values the stock at 183p, roughly in line with the current share price.
Exhibit 1: Financial summary
£'000s |
2015 |
2016 |
2017 |
2018e |
2019e |
2020e |
||
Year end 31 December |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
||||||||
Revenue |
|
|
36,106 |
45,744 |
57,164 |
56,012 |
60,125 |
61,940 |
Cost of Sales |
0 |
0 |
0 |
0 |
0 |
0 |
||
Gross Profit |
36,106 |
45,744 |
57,164 |
56,012 |
60,125 |
61,940 |
||
EBITDA |
|
|
1,548 |
3,995 |
5,619 |
6,160 |
6,689 |
6,984 |
Adjusted operating profit |
|
|
818 |
3,214 |
4,520 |
4,983 |
5,472 |
5,761 |
Amort'n of acq'd intangibles |
0 |
0 |
(1,982) |
(1,250) |
(1,200) |
(1,150) |
||
Exceptionals |
0 |
(458) |
2,075 |
0 |
0 |
0 |
||
Share based payments |
(11) |
14 |
0 |
(45) |
(50) |
(55) |
||
Operating Profit |
807 |
2,770 |
4,613 |
3,688 |
4,222 |
4,556 |
||
Net Interest |
(196) |
(185) |
(710) |
(567) |
(450) |
(400) |
||
Associates |
3 |
17 |
39 |
0 |
0 |
0 |
||
Profit Before Tax (norm) |
|
|
625 |
3,046 |
3,849 |
4,416 |
5,022 |
5,361 |
Profit Before Tax (FRS 3) |
|
|
614 |
2,602 |
3,942 |
3,121 |
3,772 |
4,156 |
Tax |
(241) |
(380) |
(593) |
(874) |
(1,243) |
(1,340) |
||
Profit After Tax (norm) |
384 |
2,666 |
3,256 |
3,542 |
3,779 |
4,021 |
||
Profit After Tax (FRS 3) |
373 |
2,222 |
3,349 |
2,247 |
2,529 |
2,816 |
||
Average Number of Shares Outstanding (m) |
29.0 |
29.0 |
29.2 |
29.4 |
29.7 |
30.0 |
||
EPS - normalised (p) |
|
|
1.3 |
9.2 |
10.0 |
12.0 |
12.7 |
13.4 |
EPS - FRS 3 (p) |
|
|
1.3 |
7.6 |
11.5 |
7.6 |
8.5 |
9.4 |
Dividend per share (p) |
1.78 |
1.96 |
2.16 |
2.38 |
2.62 |
2.88 |
||
Gross Margin (%) |
100.0 |
100.0 |
100.0 |
100.0 |
100.0 |
100.0 |
||
EBITDA Margin (%) |
4.3 |
8.7 |
9.8 |
11.0 |
11.1 |
11.3 |
||
Operating Margin (%) |
2.3 |
7.0 |
7.9 |
8.9 |
9.1 |
9.3 |
||
BALANCE SHEET |
||||||||
Fixed Assets |
|
|
16,553 |
31,955 |
30,465 |
29,159 |
27,944 |
26,809 |
Intangible Assets |
7,831 |
22,441 |
21,086 |
19,836 |
18,636 |
17,486 |
||
Tangible Assets |
8,635 |
9,057 |
9,261 |
9,205 |
9,190 |
9,205 |
||
Deferred tax asset & associates |
87 |
457 |
118 |
118 |
118 |
118 |
||
Current Assets |
|
|
17,839 |
27,895 |
33,333 |
32,612 |
35,666 |
36,817 |
Stocks |
211 |
261 |
321 |
315 |
338 |
348 |
||
Debtors |
12,299 |
19,621 |
24,541 |
24,045 |
25,810 |
26,588 |
||
Cash |
4,352 |
6,915 |
8,021 |
7,802 |
9,068 |
9,431 |
||
Current Liabilities |
|
|
(12,003) |
(18,763) |
(23,481) |
(23,393) |
(24,655) |
(24,894) |
Creditors |
(8,699) |
(14,959) |
(21,191) |
(21,353) |
(22,865) |
(23,354) |
||
Short term borrowings |
(3,304) |
(3,804) |
(2,290) |
(2,040) |
(1,790) |
(1,540) |
||
Long Term Liabilities |
|
|
(2,333) |
(18,374) |
(14,603) |
(11,690) |
(10,479) |
(8,268) |
Long term borrowings |
(2,007) |
(13,355) |
(11,667) |
(8,754) |
(7,543) |
(5,332) |
||
Other long term liabilities |
(326) |
(5,019) |
(2,936) |
(2,936) |
(2,936) |
(2,936) |
||
Net Assets |
|
|
20,056 |
22,713 |
25,714 |
26,688 |
28,476 |
30,464 |
CASH FLOW |
||||||||
Operating Cash Flow |
|
|
1,570 |
3,442 |
10,369 |
6,831 |
6,388 |
6,674 |
Net Interest |
(196) |
(185) |
(710) |
(567) |
(450) |
(400) |
||
Tax |
(583) |
(1,250) |
147 |
(930) |
(1,283) |
(1,405) |
||
Capex |
(619) |
(663) |
(1,255) |
(1,120) |
(1,202) |
(1,239) |
||
Acquisitions/disposals |
(889) |
(7,521) |
82 |
(617) |
0 |
0 |
||
Financing |
(14) |
15 |
(131) |
0 |
0 |
0 |
||
Dividends |
(340) |
(671) |
(586) |
(652) |
(725) |
(806) |
||
Net Cash Flow |
(1,071) |
(6,833) |
7,916 |
2,944 |
2,728 |
2,824 |
||
Opening net debt/(cash) |
|
|
(328) |
959 |
10,244 |
5,936 |
2,992 |
265 |
Other including foreign exchange |
(216) |
(2,452) |
(3,608) |
0 |
0 |
0 |
||
Closing net debt/(cash) |
|
|
959 |
10,244 |
5,936 |
2,992 |
265 |
(2,559) |
Source: SCISYS, Edison Investment Research. Note: IFRS15 is applied from 1 January 2018.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com DISCLAIMER |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 295 Madison Avenue, 18th Floor 10017, New York US |
Sydney +61 (0)2 8249 8342 Level 4, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 295 Madison Avenue, 18th Floor 10017, New York US |
Sydney +61 (0)2 8249 8342 Level 4, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia |
Research: Healthcare
InMed continues to make progress on its biosynthesis platform, optimizing the genes that lead E. coli to express the cannabinoids and scaling up the fermentation process, both crucial steps needed to achieve commercial scale to address the market. InMed is also optimizing the formulation for INM-750 for epidermolysis bullosa (EB). A final formulation is expected by the end of 2018. The company is also conducting pharmacology, toxicology and other pre-clinical studies in preparation for detailed discussions with regulatory authorities, which it expects to occur in H119. InMed is on track for an IND filing in H219.